Keywords
Last Name
Institution

Patrick A. Flume

TitleEndowed Chair, Powers-Huggins Endowed Chair for Cystic Fibrosis
InstitutionMedical University of South Carolina
DepartmentPulmonary
AddressP.O. Box MSC 630
Clinical Science Bldg. - 96 Jonathan Lucas St.
Phone843-792-3167
Fax843-876-2057
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Patrick Flume joined the faculty of the Pulmonary and Critical Care Division at the Medical University of South Carolina in 1993. He is now a Professor of Medicine and Pediatrics, overseeing a rapidly growing Cystic Fibrosis Center. Though he continues to practice general pulmonary and critical care medicine, his primary interests are in CF and bronchiectasis, and chronic lung infections, including nontuberculous mycobacteria.

    The MUSC Cystic Fibrosis Center is the principal CF program in South Carolina. They provide state-of-the-art care to patients and families with CF; provide primary educator of clinicians and basic scientists in the field of CF; and perform basic and clinical research in the field of CF. Dr. Flume is the MUSC CF Center Director and has national recognition by the national and international CF community having served on the Cystic Fibrosis Foundation Center Committee, the Adult Care Consensus Committee, the Advisory Task Force on Adult Issues, the Professional Education Committee, and as co-chair for the Pulmonary Practice Guidelines Committee.

    Dr. Flume has an active clinical research program and heads the MUSC Research Nexus.

    Collapse keywords
    Cystic Fibrosis, Lung, Vision/ Eye, Drug Studies, Pediatrics, Pulmonary, Adolescents, Healthy Volunteer Studies, Infectious Diseases, Non-interventional, Breathing, Inflammation, Stage III

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sanders DB, Ostrenga JS, Rosenfeld M, Fink AK, Schechter MS, Sawicki GS, Flume PA, Morgan WJ. Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2019 Jun 27. PMID: 31257102.
      View in: PubMed
    2. Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 Jun 25. PMID: 31253540.
      View in: PubMed
    3. Flume PA, Chalmers JD, Olivier KN. Rheumatoid arthritis-associated bronchiectasis - Authors' reply. Lancet. 2019 05 18; 393(10185):2036. PMID: 31106746.
      View in: PubMed
    4. Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin Infect Dis. 2019 May 06. PMID: 31056660.
      View in: PubMed
    5. Nichols DP, Durmowicz AG, Field A, Flume PA, VanDevanter DR, Mayer-Hamblett N. Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Ann Am Thorac Soc. 2019 May; 16(5):534-539. PMID: 30658043.
      View in: PubMed
    6. Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J Cyst Fibros. 2019 Mar; 18(2):236-243. PMID: 30709744.
      View in: PubMed
    7. Flume PA. The study of CFTR modulators in the very young. Lancet Respir Med. 2019 Apr; 7(4):287-289. PMID: 30686766.
      View in: PubMed
    8. Bell SC, Castellani C, Flume PA. JCF - progress in 2018. J Cyst Fibros. 2019 Jan; 18(1):1-5. PMID: 30665544.
      View in: PubMed
    9. Flume PA, Suthoff ED, Kosinski M, Marigowda G, Quittner AL. Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros. 2018 Dec 23. PMID: 30587335.
      View in: PubMed
    10. Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ, van Ingen J, Coulter C, Nezamis J, Winthrop KL. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 Dec 15; 198(12):1559-1569. PMID: 30216086.
      View in: PubMed
    11. Szentpetery S, Flume PA. Optimizing outcomes of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2018 11; 24(6):606-611. PMID: 30124523.
      View in: PubMed
    12. Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J. Antimicrobial resistance in cystic fibrosis: Does it matter? J Cyst Fibros. 2018 Nov; 17(6):687-689. PMID: 30270113.
      View in: PubMed
    13. Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ. Defining antimicrobial resistance in cystic fibrosis. J Cyst Fibros. 2018 Nov; 17(6):696-704. PMID: 30266518.
      View in: PubMed
    14. Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018 09 08; 392(10150):880-890. PMID: 30215383.
      View in: PubMed
    15. Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE. "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis. J Clin Microbiol. 2018 09; 56(9). PMID: 29875191.
      View in: PubMed
    16. Flume PA, Winthrop KL. Mycobacterial Disease: Evolving Concepts. Semin Respir Crit Care Med. 2018 Jun; 39(3):269. PMID: 30071542.
      View in: PubMed
    17. Furukawa BS, Flume PA. Nontuberculous Mycobacteria in Cystic Fibrosis. Semin Respir Crit Care Med. 2018 Jun; 39(3):383-391. PMID: 30071553.
      View in: PubMed
    18. Jennings MT, Flume PA. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Ann Am Thorac Soc. 2018 Aug; 15(8):897-902. PMID: 29812963.
      View in: PubMed
    19. Forrester JB, Steed LL, Santevecchi BA, Flume P, Palmer-Long GE, Bosso JA. In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates. Open Forum Infect Dis. 2018 Jul; 5(7):ofy158. PMID: 30046642.
      View in: PubMed
    20. Goss CH, Somayaji R, Flume PA. Benefits of set length antibiotic treatment for pulmonary exacerbations. Lancet Respir Med. 2018 08; 6(8):575-577. PMID: 29960882.
      View in: PubMed
    21. West NE, Flume PA. Unmet needs in cystic fibrosis: the next steps in improving outcomes. Expert Rev Respir Med. 2018 07; 12(7):585-593. PMID: 29855230.
      View in: PubMed
    22. Bell L, Gentilin S, Sonne S, Mauney T, Flume P. Providing Restricted Access to an Electronic Medical Record for Research Monitoring. Clin Res (Alex). 2018; 32(3). PMID: 30613763.
      View in: PubMed
    23. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 Mar; 17(2):153-178. PMID: 29506920.
      View in: PubMed
    24. Brown KL, Flume PA. Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis. J Genet Couns. 2018 09; 27(5):1049-1054. PMID: 29429040.
      View in: PubMed
    25. Sonne S, Gentilin S, Sampson RR, Bell L, Mauney T, Young S, Bright K, Flume P. Response to Commentary: Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review-A CTSA Institution's Experience. J Empir Res Hum Res Ethics. 2018 04; 13(2):148. PMID: 29345186.
      View in: PubMed
    26. Sonne S, Gentilin S, Sampson RR, Bell L, Mauney T, Young S, Bright K, Flume P. Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review: A CTSA Institution's Experience. J Empir Res Hum Res Ethics. 2018 04; 13(2):139-144. PMID: 29345179.
      View in: PubMed
    27. Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemp Clin Trials. 2018 01; 64:35-40. PMID: 29170074.
      View in: PubMed
    28. Bell SC, Castellani C, Flume PA. Learning's from the Editors Desk - 2017. J Cyst Fibros. 2017 11; 16(6):645-646. PMID: 29150008.
      View in: PubMed
    29. Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 01; 17(1):83-88. PMID: 28651844.
      View in: PubMed
    30. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017 06; 49(6). PMID: 28596426.
      View in: PubMed
    31. Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599. PMID: 28460885.
      View in: PubMed
    32. West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017 Sep; 16(5):600-606. PMID: 28457954.
      View in: PubMed
    33. VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. J Cyst Fibros. 2017 09; 16(5):607-615. PMID: 28438499.
      View in: PubMed
    34. Olivier KN, Griffith DE, Eagle G, McGinnis JP, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2017 03 15; 195(6):814-823. PMID: 27748623.
      View in: PubMed
    35. Flume PA, VanDevanter DR. The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans? Ann Intern Med. 2017 04 18; 166(8):599-600. PMID: 28289748.
      View in: PubMed
    36. Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379. PMID: 28209466.
      View in: PubMed
    37. Flume PA, VanDevanter DR. The challenges of maintaining momentum in CF drug development and approval - Commentary. J Cyst Fibros. 2017 03; 16(2):170-171. PMID: 28179070.
      View in: PubMed
    38. Bell SC, Flume PA. Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough? Thorax. 2017 04; 72(4):297-299. PMID: 28077615.
      View in: PubMed
    39. Elborn JS, Davies J, Mall MA, Flume PA, Plant B. Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapy. J Cyst Fibros. 2017 01; 16(1):163-164. PMID: 27986495.
      View in: PubMed
    40. Barry PJ, Flume PA. Bronchodilators in cystic fibrosis: a critical analysis. Expert Rev Respir Med. 2017 01; 11(1):13-20. PMID: 27718752.
      View in: PubMed
    41. Flume PA, VanDevanter DR. Efficacy measures for clinical trials: A review series. J Cyst Fibros. 2016 07; 15(4):415. PMID: 27316664.
      View in: PubMed
    42. Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815. PMID: 27233377.
      View in: PubMed
    43. Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA. Corrigendum to "Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study" [J Cyst Fibros (2015) 632-638]. J Cyst Fibros. 2016 Sep; 15(5):e54-e55. PMID: 27211571.
      View in: PubMed
    44. Raja TH, Flume PA. Adults with cystic fibrosis in Portugal: A first step towards improvement. Rev Port Pneumol (2006). 2016 May-Jun; 22(3):139-40. PMID: 27256624.
      View in: PubMed
    45. VanDevanter DR, Flume PA, Morris N, Konstan MW. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):783-790. PMID: 27139161.
      View in: PubMed
    46. Nadig TR, Flume PA. Aerosolized Antibiotics for Patients with Bronchiectasis. Am J Respir Crit Care Med. 2016 Apr 01; 193(7):808-10. PMID: 27035784.
      View in: PubMed
    47. Flume PA. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):139-40. PMID: 27062882.
      View in: PubMed
    48. Elborn JS, Flume PA, Cohen F, Loutit J, VanDevanter DR. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J Cyst Fibros. 2016 09; 15(5):634-40. PMID: 26935334.
      View in: PubMed
    49. Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 07; 15(4):495-502. PMID: 26852040.
      View in: PubMed
    50. Gruber JD, Chen W, Parnham S, Beauchesne K, Moeller P, Flume PA, Zhang YM. The role of 2,4-dihydroxyquinoline (DHQ) in Pseudomonas aeruginosa pathogenicity. PeerJ. 2016; 4:e1495. PMID: 26788419.
      View in: PubMed
    51. Konstan MW, Flume PA, Galeva I, Wan R, Debonnett LM, Maykut RJ, Angyalosi G. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr; 51(4):372-8. PMID: 26709158.
      View in: PubMed
    52. Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW. Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2016 Feb; 169:116-21.e2. PMID: 26388208.
      View in: PubMed
    53. Sanders DB, Fink A, Mayer-Hamblett N, Schechter MS, Sawicki GS, Rosenfeld M, Flume PA, Morgan WJ. Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1. PMID: 26340874.
      View in: PubMed
    54. Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33. PMID: 26321218.
      View in: PubMed
    55. Hurley MN, Prayle AP, Flume P. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database Syst Rev. 2015 Jul 30; (7):CD009730. PMID: 26226131.
      View in: PubMed
    56. Hurley MN. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatr Respir Rev. 2015 Sep; 16(4):246-8. PMID: 26298057.
      View in: PubMed
    57. Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul; 3(7):524-33. PMID: 26070913.
      View in: PubMed
    58. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 07 16; 373(3):220-31. PMID: 25981758.
      View in: PubMed
    59. Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016 Mar; 71(3):223-9. PMID: 25911223.
      View in: PubMed
    60. Flume PA, Aitken ML, Bilton D, Agent P, Charlton B, Forster E, Fox HG, Hebestreit H, Kolbe J, Zuckerman JB, Button BM. Optimising inhaled mannitol for cystic fibrosis in an adult population. Breathe (Sheff). 2015 Mar; 11(1):39-48. PMID: 26306102.
      View in: PubMed
    61. Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA. Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. J Cyst Fibros. 2015 Sep; 14(5):632-8. PMID: 25725985.
      View in: PubMed
    62. Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14. PMID: 25592656.
      View in: PubMed
    63. Bhattacharyya SB, Calado F, Priedane E, Shirore RM, Haworth CS, Flume PA, Sonathi V, Thomas SK. A De-Novo Economic Model to Assess Clinical and Economic Consequences of Bronchiectasis. Value Health. 2014 Nov; 17(7):A551. PMID: 27201797.
      View in: PubMed
    64. Flume PA, VanDevanter DR. Clinical applications of pulmonary delivery of antibiotics. Adv Drug Deliv Rev. 2015 May; 85:1-6. PMID: 25453268.
      View in: PubMed
    65. Bradley JM, Koker P, Deng Q, Moroni-Zentgraf P, Ratjen F, Geller DE, Elborn JS. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PLoS One. 2014; 9(9):e106195. PMID: 25188297.
      View in: PubMed
    66. Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O'Riordan TG. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep; 2(9):738-49. PMID: 25154045.
      View in: PubMed
    67. Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, Metersky ML, Flume PA, Lewis SA, McKevitt M, Montgomery AB, O'Riordan TG, Barker AF. A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest. 2014 Aug; 146(2):437-448. PMID: 24626872.
      View in: PubMed
    68. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzenberg SJ, Sermet-Gaudelus I, Southern KW, Taccetti G, Ullrich G, Wolfe S. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014 May; 13 Suppl 1:S23-42. PMID: 24856775.
      View in: PubMed
    69. Hill AT, Flume PA. Lung clearance index. A potential quantitative tool to assess treatment response in bronchiectasis? Am J Respir Crit Care Med. 2014 Mar 01; 189(5):510-1. PMID: 24579835.
      View in: PubMed
    70. Gilley SK, Stenbit AE, Pasek RC, Sas KM, Steele SL, Amria M, Bunni MA, Estell KP, Schwiebert LM, Flume P, Gooz M, Haycraft CJ, Yoder BK, Miller C, Pavlik JA, Turner GA, Sisson JH, Bell PD. Deletion of airway cilia results in noninflammatory bronchiectasis and hyperreactive airways. Am J Physiol Lung Cell Mol Physiol. 2014 Jan; 306(2):L162-9. PMID: 24213915.
      View in: PubMed
    71. Stenbit AE, Bullington WM, Heh JL, Flume PA. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. J Cyst Fibros. 2013 Jul; 12(4):403-6. PMID: 23266092.
      View in: PubMed
    72. Bilton D, Bellon G, Charlton B, Cooper P, De Boeck K, Flume PA, Fox HG, Gallagher CG, Geller DE, Haarman EG, Hebestreit HU, Kolbe J, Lapey A, Robinson P, Wu J, Zuckerman JB, Aitken ML. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros. 2013 Jul; 12(4):367-76. PMID: 23234802.
      View in: PubMed
    73. Döring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012 Dec; 11(6):461-79. PMID: 23137712.
      View in: PubMed
    74. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep; 142(3):718-724. PMID: 22383668.
      View in: PubMed
    75. Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Med. 2012 Aug 10; 10:88. PMID: 22883684.
      View in: PubMed
    76. Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, Zuckerman JB, Charlton B. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52. PMID: 22198974.
      View in: PubMed
    77. Lo D, VanDevanter DR, Flume P, Smyth A. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med. 2011 Dec; 105 Suppl 2:S9-17. PMID: 22208548.
      View in: PubMed
    78. Flume PA. Chronic cystic fibrosis respiratory infections: where do we go from here? Introduction. Respir Med. 2011 Dec; 105 Suppl 2:S1. PMID: 22208545.
      View in: PubMed
    79. VanDevanter DR, Ballmann M, Flume PA. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respir Med. 2011 Dec; 105 Suppl 2:S18-23. PMID: 22208544.
      View in: PubMed
    80. Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2011 Nov; 17(6):442-7. PMID: 21881509.
      View in: PubMed
    81. Tomov SV, Flume PA, Stenbit AE, Ullian ME. Prerenal azotemia from excessive sweating in an adult with a cystic fibrosis gene mutation. Indian J Nephrol. 2011 Jul; 21(3):194-7. PMID: 21886981.
      View in: PubMed
    82. Flume PA. Pneumothorax in cystic fibrosis. Curr Opin Pulm Med. 2011 Jul; 17(4):220-5. PMID: 21460730.
      View in: PubMed
    83. Mogayzel PJ, Flume PA. Update in cystic fibrosis 2010. Am J Respir Crit Care Med. 2011 Jun 15; 183(12):1620-4. PMID: 21693717.
      View in: PubMed
    84. Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011 Jun; 55(6):2636-40. PMID: 21444699.
      View in: PubMed
    85. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1510-6. PMID: 21471106.
      View in: PubMed
    86. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61. PMID: 21075062.
      View in: PubMed
    87. Flume PA, Mogayzel PJ, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010 Aug 01; 182(3):298-306. PMID: 20675678.
      View in: PubMed
    88. Mogayzel PJ, Flume PA. Update in cystic fibrosis 2009. Am J Respir Crit Care Med. 2010 Mar 15; 181(6):539-44. PMID: 20208039.
      View in: PubMed
    89. Barto TL, Flume PA. Treatment of pulmonary exacerbations in adult cystic fibrosis patients: a review. Hosp Pract (1995). 2010 Feb; 38(1):26-34. PMID: 20469621.
      View in: PubMed
    90. Flume PA. Smoothing the transition from pediatric to adult care: lessons learned. Curr Opin Pulm Med. 2009 Nov; 15(6):611-4. PMID: 19696678.
      View in: PubMed
    91. O'Sullivan BP, Flume P. The clinical approach to lung disease in patients with cystic fibrosis. Semin Respir Crit Care Med. 2009 Oct; 30(5):505-13. PMID: 19760538.
      View in: PubMed
    92. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009 Nov 01; 180(9):802-8. PMID: 19729669.
      View in: PubMed
    93. Flume PA, Ciolino J, Gray S, Lester MK. Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Sep; 8(5):321-5. PMID: 19665944.
      View in: PubMed
    94. Lester MK, Flume PA. Airway-clearance therapy guidelines and implementation. Respir Care. 2009 Jun; 54(6):733-50; discussion 751-3. PMID: 19467161.
      View in: PubMed
    95. Flume PA. Pulmonary complications of cystic fibrosis. Respir Care. 2009 May; 54(5):618-27. PMID: 19393106.
      View in: PubMed
    96. Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009 Apr; 54(4):522-37. PMID: 19327189.
      View in: PubMed
    97. Ghegan MD, Wise SK, White DR, Flume PA, Bowman CM, Virella-Lowell I, Schlosser RJ. Cost-effective airway cultures in the cystic fibrosis patient. Am J Otolaryngol. 2009 May-Jun; 30(3):150-2. PMID: 19410117.
      View in: PubMed
    98. Flume PA, Stenbit A. Making the diagnosis of cystic fibrosis. Am J Med Sci. 2008 Jan; 335(1):51-4. PMID: 18195584.
      View in: PubMed
    99. Stenbit A, Flume PA. Pulmonary complications in adult patients with cystic fibrosis. Am J Med Sci. 2008 Jan; 335(1):55-9. PMID: 18195585.
      View in: PubMed
    100. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):957-69. PMID: 17761616.
      View in: PubMed
    101. Ford D, Flume PA. Impact of lung transplantation on site of death in cystic fibrosis. J Cyst Fibros. 2007 Nov 30; 6(6):391-5. PMID: 17448734.
      View in: PubMed
    102. Woodworth BA, Ahn C, Flume PA, Schlosser RJ. The delta F508 mutation in cystic fibrosis and impact on sinus development. Am J Rhinol. 2007 Jan-Feb; 21(1):122-7. PMID: 17283574.
      View in: PubMed
    103. Garwood S, Flume PA, Ravenel J. Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis. Pediatr Pulmonol. 2006 Jul; 41(7):683-7. PMID: 16703584.
      View in: PubMed
    104. Heaney DL, Flume P, Hamilton L, Lyon E, Wolff DJ. Detection of an apparent homozygous 3120G>A cystic fibrosis mutation on a routine carrier screen. J Mol Diagn. 2006 Feb; 8(1):137-40. PMID: 16436646.
      View in: PubMed
    105. Sheridan MB, Fong P, Groman JD, Conrad C, Flume P, Diaz R, Harris C, Knowles M, Cutting GR. Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum Mol Genet. 2005 Nov 15; 14(22):3493-8. PMID: 16207733.
      View in: PubMed
    106. Flume PA, Strange C, Ye X, Ebeling M, Hulsey T, Clark LL. Pneumothorax in cystic fibrosis. Chest. 2005 Aug; 128(2):720-8. PMID: 16100160.
      View in: PubMed
    107. Flume PA, Yankaskas JR, Ebeling M, Hulsey T, Clark LL. Massive hemoptysis in cystic fibrosis. Chest. 2005 Aug; 128(2):729-38. PMID: 16100161.
      View in: PubMed
    108. Davé S, Honney S, Raymond J, Flume PA. An unusual presentation of cystic fibrosis in an adult. Am J Kidney Dis. 2005 Mar; 45(3):e41-4. PMID: 15754262.
      View in: PubMed
    109. Flume P, Gray S, Bowman CM, Kerrigan C, Lester M, Virella-Lowell I. Emergency preparedness for the chronically ill. Am J Nurs. 2005 Mar; 105(3):68-72. PMID: 15729049.
      View in: PubMed
    110. Lester MK, Flume PA, Gray SL, Anderson D, Bowman CM. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care. 2004 Dec; 49(12):1504-8. PMID: 15571641.
      View in: PubMed
    111. Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2004 Jan; 48(1):281-4. PMID: 14693551.
      View in: PubMed
    112. Flume PA, Taylor LA, Anderson DL, Gray S, Turner D. Transition programs in cystic fibrosis centers: perceptions of team members. Pediatr Pulmonol. 2004 Jan; 37(1):4-7. PMID: 14679482.
      View in: PubMed
    113. Flume PA. Airway clearance techniques. Semin Respir Crit Care Med. 2003 Dec; 24(6):727-36. PMID: 16088588.
      View in: PubMed
    114. Douglas G, Bird K, Flume P, Silver R, Bolster M. Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Sep; 30(9):2064-9. PMID: 12966617.
      View in: PubMed
    115. Flume PA. Pneumothorax in cystic fibrosis. Chest. 2003 Jan; 123(1):217-21. PMID: 12527625.
      View in: PubMed
    116. Silvestri GA, Sherman C, Williams T, Leong SS, Flume P, Turrisi A. Caring for the dying patient with lung cancer. Chest. 2002 Sep; 122(3):1028-36. PMID: 12226050.
      View in: PubMed
    117. Flume PA. Medicinal treatment of intractable dyspnea in terminally ill patients. J S C Med Assoc. 2002 Aug; 98(4):196-9. PMID: 12216382.
      View in: PubMed
    118. Anderson DL, Flume PA, Hardy KK, Gray S. Transition programs in cystic fibrosis centers: perceptions of patients. Pediatr Pulmonol. 2002 May; 33(5):327-31. PMID: 11948976.
      View in: PubMed
    119. Highland KB, Flume PA. A "story" of a woman with cystic fibrosis. Chest. 2002 May; 121(5):1704-7. PMID: 12006467.
      View in: PubMed
    120. Avendano CE, Flume PA, Silvestri GA, King LB, Reed CE. Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002 Mar; 73(3):922-6. PMID: 11899202.
      View in: PubMed
    121. Kuhn RJ, Flume PA. Treatment options for cystic fibrosis: case study and panel discussion. Pharmacotherapy. 2002 Mar; 22(3 Pt 2):86S-87S. PMID: 11898886.
      View in: PubMed
    122. Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy. 2002 Mar; 22(3 Pt 2):71S-79S. PMID: 11898884.
      View in: PubMed
    123. Avendano CE, Flume PA, Baliga P, Lewin DN, Strange C, Reuben A. Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transpl. 2001 Dec; 7(12):1081-4. PMID: 11753911.
      View in: PubMed
    124. Highland KB, Flume PA. A 12-year-old girl with dyspnea and a normal chest radiographic finding. Hypersensitivity pneumonitis. Chest. 2001 Oct; 120(4):1372-6. PMID: 11591583.
      View in: PubMed
    125. Flume PA, Anderson DL, Hardy KK, Gray S. Transition programs in cystic fibrosis centers: perceptions of pediatric and adult program directors. Pediatr Pulmonol. 2001 Jun; 31(6):443-50. PMID: 11389577.
      View in: PubMed
    126. Anderson DL, Flume PA, Hardy KK. Psychological functioning of adults with cystic fibrosis. Chest. 2001 Apr; 119(4):1079-84. PMID: 11296173.
      View in: PubMed
    127. Benzo R, Flume PA, Turner D, Tempest M. Effect of pulmonary rehabilitation on quality of life in patients with COPD: the use of SF-36 summary scores as outcomes measures. J Cardiopulm Rehabil. 2000 Jul-Aug; 20(4):231-4. PMID: 10955263.
      View in: PubMed
    128. Nichols PL, Flume P. Complications of cystic fibrosis in adults. J S C Med Assoc. 2000 Mar; 96(3):112-7. PMID: 10812878.
      View in: PubMed
    129. Bosso JA, Bonapace CR, Flume PA, White RL. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy. 1999 May; 19(5):620-6. PMID: 10331825.
      View in: PubMed
    130. Flume PA. Cystic fibrosis: when to consider lung transplantation? Chest. 1998 May; 113(5):1159-61. PMID: 9596287.
      View in: PubMed
    131. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method. Antimicrob Agents Chemother. 1997 Nov; 41(11):2527-32. PMID: 9371361.
      View in: PubMed
    132. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 1997 Sep; 41(9):2053-6. PMID: 9303416.
      View in: PubMed
    133. Flume PA. Current and novel therapies for cystic fibrosis. J S C Med Assoc. 1996 Sep; 92(9):381-8. PMID: 8854578.
      View in: PubMed
    134. Flume PA, Eldridge FL, Edwards LJ, Mattison LE. Relief of the 'air hunger' of breathholding. A role for pulmonary stretch receptors. Respir Physiol. 1996 Mar; 103(3):221-32. PMID: 8738898.
      View in: PubMed
    135. Flume PA, Eldridge FL, Edwards LJ, Houser LM. Relief of distress of breathholding: separate effects of expiration and inspiration. Respir Physiol. 1995 Jul; 101(1):41-6. PMID: 8525120.
      View in: PubMed
    136. Judson MA, Flume PA, West DC, McFadden C, Crumbley AJ, Handy JR. The MUSC lung transplantation program: the first year's experience. J S C Med Assoc. 1995 May; 91(5):223-7. PMID: 7776624.
      View in: PubMed
    137. Steinbach S, Sun L, Jiang RZ, Flume P, Gilligan P, Egan TM, Goldstein R. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med. 1994 Oct 13; 331(15):981-7. PMID: 7521938.
      View in: PubMed
    138. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1601-7. PMID: 7516251.
      View in: PubMed
    139. Flume PA, Egan TM, Westerman JH, Paradowski LJ, Yankaskas JR, Detterbeck FC, Mill MR. Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant. 1994 Jan-Feb; 13(1 Pt 1):15-21; discussion 22-3. PMID: 7513185.
      View in: PubMed
    140. Flume PA, Eldridge FL, Edwards LJ, Houser LM. The Fowler breathholding study revisited: continuous rating of respiratory sensation. Respir Physiol. 1994 Jan; 95(1):53-66. PMID: 8153453.
      View in: PubMed
    141. flume PA. test.
    Flume's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _